← Back to headlines
Sellas Life Stock Drops 13% Amid Lack of Updates on ALM Drug Candidate
Shares of biotechnology company Sellas Life fell sharply after the firm failed to provide investor updates regarding its lead drug candidate, ALM. Market participants remain cautious due to the lack of clinical or regulatory progress disclosures.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
